NT-I7 is a Unique T Cell Amplifier

Interleukin-7 (IL-7) is Central to T Lymphocyte Development and Survival
IL-7 plays a key role in T cell development and survival1,2. When T cell numbers are low, IL-7 has the capacity to stimulate T cell expansion. However, as a homeostatic cytokine, IL-7 levels do not rise dramatically, and T cell recovery is often a slow process3.

IL-7 acts through the IL-7 receptor (IL-7R), which is expressed on naïve and memory CD4+ and CD8+ T cells. Thus, IL-7 promotes the proliferation, maintenance, and functionality of these key T cell subsets mediating immune responses. On the other hand, regulatory T cells, a subset involved in limiting immune responses, express low levels of IL-7R and are less reactive to IL-74.

At NeoImmuneTech, we are exploring the utility of NT-I7-related therapeutics in enhancing immune function.
NT-I7 is a More Potent, Stable, and Long-Acting Human IL-7
NT-I7 (efineptakin alfa) is a human IL-7 fusion protein that overcomes the key limitations of endogenous IL-7. NT-I7 has an IL-7 domain that directly promotes T cell development and an engineered N-terminus domain that overcomes the structural instability of IL-7 and enables mass production. 
The HyFc® domain extends the half-life of IL-7, thereby enhancing bioavailability which provides better potency and stability.
NT-I7 Boosts T Cell Numbers and Functionality to Enhance Immune Function and Potentially Provide Greater Therapeutic Benefits to Patients
At NeoImmuneTech, we focus on developing NT-I7 in immuno-oncology and infectious disease. NT-I7 utilizes multiple mechanisms to enhance immune function. Homeostatic Proliferation Increased Tumor Infiltrating Lymphocytes (TIL) Increased T-Cell Receptor (TCR) Clonality in TIL Induction of T cell Stemness See Our Scientific Publications

1. Mazzucchelli, Renata, and Scott K. Durum. "Interleukin-7 receptor expression: intelligent design." Nature Reviews Immunology 7.2 (2007): 144-154.
2. Fry, Terry J., and Crystal L. Mackall. "Interleukin-7: from bench to clinic." Blood, The Journal of the American Society of Hematology 99.11 (2002): 3892-3904.
3. Ponchel, Frederique, et al. "Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia." Arthritis Res Ther 7.1 (2004): R80.
4. Seddiki, N. Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. "Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells." J Exp Med 203 (2006): 1693-1700.